Key result
Antibody-derived GPIIb-IIIa antagonists inhibited platelet prothrombinase activity by 40-50%, whereas low-molecular-weight antagonists caused significantly less or no inhibition.
Why the study?
Do antibody-derived GPIIb-IIIa antagonists reduce platelet procoagulant activity more than peptide-derived and peptidomimetic antagonists in vitro?
Population
Gel-filtered platelets (in vitro model)
Comparison
Antibody-derived GPIIb-IIIa antagonists vs Peptide-derived and peptidomimetic GPIIb-IIIa…
Design
Preclinical
Authors
Loading...
Antibody-derived GPIIb-IIIa antagonists may inhibit platelet procoagulant activity more than low-molecular-weight agents; hypothesis-generating and should not yet change practice.
Do antibody-derived GPIIb-IIIa antagonists reduce platelet procoagulant activity more than peptide-derived and peptidomimetic antagonists in vitro?
Antibody-derived GPIIb-IIIa inhibitors provide greater inhibition of platelet procoagulant activity compared to low-molecular-weight peptide and peptidomimetic inhibitors, potentially explaining differences in clinical anti-thrombotic efficacy.
Lages et al. (2001) studied this question. Antibody-derived GPIIb-IIIa antagonists (c7E3 Fab and m10E5 IgG) vs. Peptide-derived and peptidomimetic antagonists was evaluated on Platelet procoagulant activity (prothrombinase activity) and stimulated cytosolic calcium increases. Antibody-derived GPIIb-IIIa antagonists inhibited platelet prothrombinase activity by 40-50%, whereas low-molecular-weight antagonists caused significantly less or no inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: